BR112021017810A2 - Anticorpos tsg-6 e usos dos mesmos - Google Patents

Anticorpos tsg-6 e usos dos mesmos

Info

Publication number
BR112021017810A2
BR112021017810A2 BR112021017810A BR112021017810A BR112021017810A2 BR 112021017810 A2 BR112021017810 A2 BR 112021017810A2 BR 112021017810 A BR112021017810 A BR 112021017810A BR 112021017810 A BR112021017810 A BR 112021017810A BR 112021017810 A2 BR112021017810 A2 BR 112021017810A2
Authority
BR
Brazil
Prior art keywords
antibodies
tsg
pharmaceutical compositions
cancer
autoimmune disease
Prior art date
Application number
BR112021017810A
Other languages
English (en)
Portuguese (pt)
Inventor
M Mason Jacqueline
R Bray Mark
Richard Brokx
Original Assignee
Univ Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Health Network filed Critical Univ Health Network
Publication of BR112021017810A2 publication Critical patent/BR112021017810A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BR112021017810A 2019-03-12 2020-03-11 Anticorpos tsg-6 e usos dos mesmos BR112021017810A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962817152P 2019-03-12 2019-03-12
PCT/CA2020/050321 WO2020181376A1 (en) 2019-03-12 2020-03-11 Tsg-6 antibodies and uses therefor

Publications (1)

Publication Number Publication Date
BR112021017810A2 true BR112021017810A2 (pt) 2021-11-23

Family

ID=72427149

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021017810A BR112021017810A2 (pt) 2019-03-12 2020-03-11 Anticorpos tsg-6 e usos dos mesmos

Country Status (14)

Country Link
US (1) US20220153834A1 (https=)
EP (1) EP3938389A4 (https=)
JP (1) JP2022522815A (https=)
KR (1) KR20210138674A (https=)
CN (1) CN113748130A (https=)
AU (1) AU2020234533A1 (https=)
BR (1) BR112021017810A2 (https=)
CA (1) CA3129302A1 (https=)
EA (1) EA202192488A1 (https=)
IL (1) IL286216A (https=)
MX (1) MX2021010766A (https=)
SG (1) SG11202109708TA (https=)
TW (1) TW202100551A (https=)
WO (1) WO2020181376A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023192829A2 (en) * 2022-03-28 2023-10-05 University Of Florida Research Foundation, Incorporated Alpha-1 antitrypsin z- and m-specific binding proteins
TWI876557B (zh) * 2022-09-30 2025-03-11 臺北醫學大學 用於前列腺癌診斷和早期發病的單株抗體
KR102582500B1 (ko) 2022-10-27 2023-09-26 서울대학교산학협력단 Tnfaip6 -조작된 종양 세포 및 이의 이용
WO2024102759A1 (en) * 2022-11-07 2024-05-16 Board Of Regents, The University Of Texas System Methods involving detecting tnf stimulated gene 6 (tsg-6) for improving anti-tumor responses to immune therapy in cancer patients

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2896058A1 (en) * 2012-12-24 2014-07-03 Abbvie Inc. Prolactin receptor binding proteins and uses thereof
AU2015301338C1 (en) * 2014-08-04 2021-07-22 Baylor Research Institute Antagonistic anti-OX40L antibodies and methods of their use
PT3186281T (pt) * 2014-08-28 2019-07-10 Halozyme Inc Terapia de combinação com uma enzima de degradação de hialuronano e um inibidor de pontos de verificação imunológica

Also Published As

Publication number Publication date
CA3129302A1 (en) 2020-09-17
JP2022522815A (ja) 2022-04-20
AU2020234533A1 (en) 2021-09-16
MX2021010766A (es) 2021-12-10
TW202100551A (zh) 2021-01-01
SG11202109708TA (en) 2021-10-28
US20220153834A1 (en) 2022-05-19
CN113748130A (zh) 2021-12-03
WO2020181376A1 (en) 2020-09-17
IL286216A (en) 2021-10-31
EP3938389A4 (en) 2022-11-09
EA202192488A1 (ru) 2022-02-08
EP3938389A1 (en) 2022-01-19
KR20210138674A (ko) 2021-11-19

Similar Documents

Publication Publication Date Title
BR112019010943A2 (pt) métodos para o tratamento do câncer compreendendo agentes de ligação a tigit
MX2023015185A (es) Degradadores de proteinas y usos de los mismos.
BR112019004733A2 (pt) métodos de tratamento de distúrbios imunes usando proteínas de ligação a pd-1
BR112021017810A2 (pt) Anticorpos tsg-6 e usos dos mesmos
BR112019024654A2 (pt) proteína de ligação nkg2d, cd16 e ror1 ou ror2
BR112018074978A2 (pt) anticorpos para alfa-sinucleína e usos dos mesmos
BR112021017583A2 (pt) Compostos, composições e métodos para o tratamento de doença
MX2020004807A (es) Agentes radioterapeuticos y de imagenologia que se dirigen a proteina-alfa de activacion fibroblastos (fap-alfa).
UY31478A1 (es) Inhibicion del receptor para la proteina estimulante del macrofago (ron) y métodos para el tratamiento de lo mismo
MY195474A (en) Single Domain Antibody and Derivative Proteins Thereof Against Programmed Death Ligand (Pdl1)
MX2019011117A (es) Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos.
BR112019005587A2 (pt) proteínas de ligação recombinantes e sua utilização
CY1124143T1 (el) Οστικες μορφογενετικες πρωτεϊνες
MX378806B (es) Inhibidores de la arginasa y sus aplicaciones terapéuticas.
EA202191769A1 (ru) Тубулизины и конъюгаты белок-тубулизин
BR112019007453A2 (pt) organonitro de sulfoxialquila e compostos relacionados e composições farmacêuticas para uso em medicina
BR112018072118A2 (pt) anticorpos de interferona beta e usos dos mesmos
MX2021010041A (es) Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt.
MX2022002056A (es) Compuestos para el tratamiento de enfermedad respiratoria bovina o porcina.
EA201990988A1 (ru) Антитела против chikv и пути их применения
MX2022015966A (es) Anticuerpos y metodos para tratar enfermedades asociadas a claudina.
BR112023018378A2 (pt) Moléculas de ligação a lilrb1 e lilrb2 e usos para as mesmas
CL2022000294A1 (es) Composiciones biofarmacéuticas y procedimientos conexos.
BR112021014911A2 (pt) Belantamabe mafodotina em combinação com pembrolizumabe para tratamento de câncer
BR112021016102A2 (pt) Moléculas de ligação a fcmr e usos das mesmas

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.